The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.

The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.

Autolus Therapeutics plc has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product by the Galien Foundation, recognizing excellence in its next-generation T cell therapy development. The award was presented by a committee of 12 UK healthcare experts and reflects the company's commitment to translating scientific research into cancer and autoimmune disease treatments.

Autolus Therapeutics plc announced it will present at William Blair's 46th Annual Growth Stock Conference on June 2, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026, with CEO Dr. Christian Itin as presenter. The company also announced the online publication of an abstract for the American Society of Clinical Oncology Annual Meeting 2026 and reported its Q1 2026 financial results.

Autolus Therapeutics reported $74.3 million in full-year 2025 AUCATZYL net product revenue and $23.3 million in Q4 2025 revenue. The company launched AUCATZYL in the UK following NICE approval and expects 2026 revenue of $120-135 million with a shift to positive gross margin. Real-world data from the ROCCA consortium confirmed high clinical activity with favorable safety profiles. The company is advancing obe-cel in multiple indications including pediatric ALL, lupus nephritis, and progressive MS, with clinical data expected throughout 2026-2028.

Autolus Therapeutics plc announced participation in two upcoming investor conferences in March 2026 (TD Cowen Health Care Conference on March 3 and Jefferies Biotech on the Beach Summit on March 10). The company also announced preliminary unaudited fourth quarter and full year 2025 net product revenue from AUCATZYL® sales, along with pipeline advancements and 2026 outlook.

The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL®, a CAR T cell therapy developed by Autolus Therapeutics, as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in England and Wales.

Autolus Therapeutics presented promising Phase 1 clinical trial data for obe-cel, a CAR T cell therapy targeting severe refractory systemic lupus erythematosus, showing high remission rates and potential for meaningful clinical impact.

Autolus Therapeutics initiated a Phase 1 clinical trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis, dosing the first patient at University College London Hospitals NHS Foundation Trust to evaluate the therapy's safety and potential efficacy.

Autolus Therapeutics reported Q2 2025 net product sales of $20.9 million for AUCATZYL®, received marketing authorization in the UK and EU, and presented long-term data from the FELIX trial demonstrating potential for long-term remission in relapsed/refractory B-ALL.

Autolus Therapeutics received European marketing authorization for AUCATZYL®, a CAR T cell therapy treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, based on successful FELIX clinical trial results.